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IntroductIon
Acute myeloid leukemia (AML) is a group of genetically 
diverse and highly aggressive hematological malignancies 
characterized by the accumulation of immature blasts. AML 
represents the most common form of acute leukemia in adults 
and accounts for most leukemia-related deaths (Siegel et al., 
2013; Döhner et al., 2015).
In recent years, genetic and molecular aberrations un-
derlying AML pathogenesis have been identified. A first ge-
netic alteration occurs in a hematopoietic stem/progenitor 
cell (HSPC), initiating clonal expansion. Subsequently, within 
this expanding clone, additional cooperating mutations are 
acquired, resulting in aberrant cell growth and a differentia-
tion block (Jan et al., 2012; Corces-Zimmerman et al., 2014; 
Shlush et al., 2014; Vasanthakumar and Godley, 2014). The 
improved understanding of disease mechanisms has allowed 
defining biologically homogenous risk groups with regard to 
treatment response, disease relapse, and overall survival (Patel 
et al., 2012; Zeisig et al., 2012). The current standard of care 
for the majority of AML patients is still a combination of cy-
tarabine with an anthracycline. However, the characterization 
of molecular abnormalities in AML has led to the develop-
ment of novel targeted agents, including FLT3, IDH1/2, and 
KIT inhibitors (Döhner et al., 2015).
AML is hierarchically organized and maintained by 
self-renewing leukemia stem cells (LSCs) that sustain a 
pool of disease-inducing cells (Reya et al., 2001; Huntly 
and Gilliland, 2005; Horton and Huntly, 2012). LSCs may 
self-renew symmetrically or divide asymmetrically into 
an LSC and a more differentiated progenitor. Changes in 
this balance toward symmetric self-renewal will lead to 
an accumulation of undifferentiated malignant cells with 
stem cell characteristics (Kreso and Dick, 2014; Bajaj et 
al., 2015). For example, this was shown for the progression 
of chronic myelogenous leukemia (CML) from chronic to 
blast phase where the fraction of symmetrically dividing 
cells increased (Jamieson et al., 2004; Wu et al., 2007; Bajaj 
et al., 2015). Concordantly, high LSC numbers as well as 
stem cell gene signatures in blasts are negative predictors 
for survival (van Rhenen et al., 2005; Pearce et al., 2006; 
Gentles et al., 2010; Eppert et al., 2011). Therefore, target-
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ing signals that induce LSC expansion, either by blocking 
proliferation or by forcing differentiation via asymmetric 
cell division may lead to resolution of the disease (Horton 
and Huntly, 2012; Bajaj et al., 2015).
CD27, a costimulatory receptor of the TNF superfamily, 
is constitutively expressed on lymphocytes and HSPCs (Nolte 
et al., 2009; Schürch et al., 2012). CD70, its only ligand, is 
expressed on activated lymphocytes and dendritic cells but 
is undetectable in homeostasis (Nolte et al., 2009). During 
immune activation, CD70/CD27 signaling promotes lym-
phocyte expansion and survival and modulates hematopoiesis 
by regulating HSPCs (Nolte et al., 2005, 2009). Interestingly, 
CD70 is aberrantly expressed on different solid tumors and 
lymphomas and was shown to induce local immunosup-
pression in glioblastoma and renal cell carcinoma (Grewal, 
2008; Nolte et al., 2009).
In this study, we demonstrate that AML blasts and AML 
stem/progenitor cells coexpress CD70 and CD27. Soluble 
CD27 (sCD27), a marker for the extent of CD70/CD27 
interactions in vivo, is considerably increased in the sera of 
newly diagnosed AML patients and is a strong prognostic 
biomarker for poor overall survival independently of age or 
cytogenetic/molecular risk group. CD70/CD27 signaling in 
AML cells induces stem cell gene signature pathways includ-
ing canonical Wnt, JAK/STAT, Hedgehog, and TGF-β signal-
ing and promotes an undifferentiated and malignant state by 
increasing symmetric cell divisions. Blocking CD70/CD27 
signaling promoted asymmetric cell divisions and differentia-
tion of AML blasts, decreased growth and colony formation, 
and induced differentiation of AML stem/progenitor cells in 
vitro. In contrast, HSPCs from healthy BM donors were not 
affected by this treatment. Blocking CD70/CD27 signaling 
Figure 1. scd27 is an independent negative 
prognostic biomarker in AML. (A) sCD27 levels in 
serum samples from newly diagnosed AML patients 
(n = 137), young (n = 5, mean of technical duplicates) 
and elderly (n = 10) healthy control subjects. (B) Kaplan- 
Meier survival curves of the entire AML patient co-
hort (n = 137) divided into two groups at the sCD27 
threshold of 577 U/ml. (C) Patient age at diagnosis, 
differentiated according to sex (left) and cytogenetic/
molecular risk group (right). (D and E) sCD27 serum 
levels (D) and Kaplan-Meier survival curves (E) of the 
different risk groups. (A, C, and D) Red lines indicate 
mean. (F–H) Kaplan-Meier survival curves for sCD27. 
(F) Favorable risk group (n = 34), sCD27 threshold 
470 U/ml. (G) Intermediate risk group (n = 68), sCD27 
threshold 586 U/ml. (H) Adverse risk group (n = 35), 
sCD27 threshold 714 U/ml. (I) Multivariate analysis 
for sCD27 adjusted for risk group, age, percentage of 
blasts in BM and blood, and leukocyte counts. Statis-
tics: (A, C [right], and D) one-way ANO VA; (C, left) Stu-
dent’s t test; (B and E–H) log-rank test; and (I) multiple 
Cox regression. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
adv., adverse; CI, confidence interval; fav., favorable; 
int., intermediate; OS, overall survival.
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Figure 2. cd27 and cd70 are expressed on AML blasts and stem/progenitor cells. (A) Representative FACS plots of CD27 and CD70 stainings (red 
lines) and the respective isotype controls (blue lines) in freshly isolated blood from two newly diagnosed AML patients with a morphological frequency of 
≥40% blasts (patient [PAT] 39, 62% blasts; and patient 153, 52% blasts). The gating strategy to identify granulocytes, blasts, and lymphocytes using CD45 
and SSC is indicated. Histograms are representative for blood blasts of n = 36 (CD27) and n = 22 (CD70) positive patients. (B and C) Mean fluorescence 
intensity (MFI) quotients of CD27 (B) and CD70 stainings (C) versus the respective isotypes on blasts and granulocytes (GCs) from the blood and BM of newly 
diagnosed AML patients. CD27 stainings: n = 42 (blood) and n = 25 (BM). CD70 stainings: n = 23 (blood) and n = 20 (BM). Blood samples had a morpho-
logical frequency of ≥40% blasts, and BM samples had a blast infiltration of ≥40%, respectively. (D) MFI quotients of CD27 and CD70 versus the respective 
isotypes on cells in the CD45dimSSClo gate (blasts) and GCs from the blood of healthy controls (n = 8). (E and F) CD27 and CD70 stainings (red lines) and the 
respective isotype controls (blue lines) on CD45dimSSCloCD34+ AML stem/progenitor cells from the BM of patient 39 (80% BM blasts; E) and CD45dimSSClo 
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by mAb in murine AML xenografts delayed disease pro-
gression, reduced the number of AML stem/progenitor cells 
and prolonged survival.
reSuLtS
scd27 is increased in sera of AML patients and is an 
independent negative prognostic biomarker
CD70/CD27 signaling is deregulated in solid tumors, lym-
phoma, and CML (Grewal, 2008; Nolte et al., 2009; Schürch 
et al., 2012; Riether et al., 2015). To investigate a potential 
role of CD70/CD27 signaling in AML, we established a liq-
uid biobank of sera and freshly isolated blood and BM sam-
ples from untreated AML patients at first diagnosis at our 
institution from 2011 to 2015. Because CD27 ligation results 
in the release of sCD27 by shedding, sCD27 can serve as a 
biomarker for the extent of CD70/CD27 interactions in vivo 
(Nolte et al., 2009). Overall, sCD27 serum levels were signifi-
cantly increased in 137 AML patients compared with healthy 
controls (Fig. 1 A). To assess serum sCD27 in relation to over-
all survival, receiver operating characteristic curve analysis was 
performed in 30% of randomly selected patients. This resulted 
in an optimal threshold of 577 U/ml to define low and high. 
Using this threshold for the entire cohort, Kaplan-Meier 
analysis revealed that patients with low serum sCD27 (≤577 
U/ml) survived significantly longer than patients with high 
serum sCD27 (Fig. 1 B).
Cytogenetic/molecular risk group and patient age 
are important established prognostic parameters in AML 
(Zeisig et al., 2012) and possibly acted as confounding fac-
tors in our analysis. Age and serum sCD27 levels did not 
lin−CD90−CD34+ AML stem/progenitor cells from the blood of patient 78 (72% blood blasts; F). In F, CD27 was stained with two different mAb clones. (G) MFI 
quotients of CD27 and CD70 versus the respective isotypes on blood CD45dimSSClolin−CD90−CD34+ AML stem/progenitor cells (LSCs; n = 9). (B, C, D, and G) 
Horizontal lines indicate the mean. (H) CD27 and CD70 stainings (red lines) and the respective isotype controls (blue lines) on CD45dimSSClolin−CD90+CD34+ 
HSPCs from one representative healthy BM donor of n = 3. See Fig. S1 (A and B) for details about the gating strategy used. Statistics: Mann–Whitney test. 
*, P < 0.05; ****, P < 0.0001. adv., adverse; fav., favorable; int., intermediate.
Figure 3. expression of cd27 and cd70 in AML blasts, stem/progenitor cells from healthy BM donors, and AML cell lines. (A and B) Expression 
of CD27 and CD70 mRNA (qRT-PCR) in FACS-sorted CD45dimSSClo AML blasts from blood (n = 26) and BM (n = 11) of newly diagnosed AML patients (A) and 
in FACS-sorted BM CD45dimSSClolin−CD90+CD34+ HSPCs from healthy BM (hBM) donors (n = 3; B). (C) Expression of CD27 (red line, top) and CD70 (red line, 
bottom) versus the respective isotype controls (blue lines) in the AML cell line U-937. One representative histogram of five (CD27) and three (CD70) is shown. 
(D) Quotients of mean fluorescence intensity (MFI) of CD27 and CD70 expression versus the respective isotype in 11 different AML cell lines. Pooled data 
from n = 2–6 (CD27) and n = 2–5 (CD70) independent experiments are shown, respectively. (E) Expression of CD27 and CD70 mRNAs in 11 different AML cell 
lines (qRT-PCR). Pooled data from n = 2 (CD27) and n = 2–5 (CD70) independent experiments are shown. Data are shown as mean ± SEM. nd, not detected.
o
n
 January 19, 2017
D
ow
nloaded from
 
Published December 28, 2016
5JEM
Figure 4. Stem cell gene expression and signaling pathways in AML and cML are linked to cd70/cd27 signaling. (A–D) Paired samples of 105 
FACS-sorted CD45dimSSCloCD33+ AML blasts from the blood and BM of 20 different newly diagnosed patients (blood, n = 20; and BM, n = 6) were cultured in 
vitro for 72 h in the presence of blocking αCD70 or control mAb. (A) Heat map of differentially expressed genes in αCD70- versus control mAb–treated blasts. 
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significantly differ between patients in the favorable, inter-
mediate, or adverse risk groups (Fig. 1, C and D; and Table 
S1). As expected, Kaplan-Meier survival curves revealed 
statistically significant survival differences between the dif-
ferent risk groups (Fig. 1 E). Furthermore, serum sCD27 
demonstrated prognostic value in subgroup analyses 
within the different risk groups (Fig. 1, F–H). In addition, 
serum sCD27 correlated significantly with the percentage 
of blasts in BM (Table S1 and not depicted). Importantly, 
however, multivariate analysis for sCD27 levels adjusted 
for risk group, patient age, percentage of blasts in BM and 
blood, and leukocyte counts confirmed serum sCD27 as a 
strong independent prognostic marker in the entire AML 
patient cohort (Fig. 1 I).
In contrast, high CD27 mRNA levels in two different 
publicly available AML microarray datasets (Valk et al., 2004; 
Metzeler et al., 2008) were associated with a favorable prog-
nosis (unpublished data). However, these datasets were not 
generated using purified blasts but with total PBMCs con-
taining immune cells such as lymphocytes that express sub-
stantially higher levels of CD27 than AML blasts (Fig. 2 A). 
In accordance, CD27 mRNA levels positively correlated with 
CD3, CD8, and CD4 mRNAs in these datasets (unpublished 
data). Therefore, high CD27 mRNA expression in AML 
PBMCs rather reflects an activated immune system that pro-
motes survival and does not necessarily indicate the extent of 
CD27 signaling on AML blasts.
These results indicate that sCD27 in serum but not 
CD27 mRNA in PBMCs is an independent negative prog-
nostic biomarker for overall survival in AML.
AML blasts and stem/progenitor cells express the tnF 
superfamily ligand–receptor pair cd70/cd27
We next intended to test whether CD27 and/or CD70 
protein can be detected on AML blasts by FACS. The 
CD45 and side scatter (SSC) gating strategy is an estab-
lished method to identify blasts (CD45dimSSClo) in pheno-
typically different AML patient samples, but the blast gate 
may include other cell populations (Borowitz et al., 1993; 
Kroft and Karandikar, 2007; Gorczyca, 2010). Accordingly, 
the blast gate can be identified in healthy individuals as well. 
We therefore only included patients in this analysis with 
a documented blast frequency of ≥40% as determined by 
morphology. Healthy donors served as negative controls. 
As expected, CD27 and CD70 were expressed on lym-
phocytes but not on granulocytes. Interestingly, CD27 and 
CD70 were detectable on AML blasts as well (Fig.  2 A). 
CD27 was detected on blasts in 36/42 (86%) blood and 
24/25 (96%) BM samples, whereas CD70 was detected in 
22/23 (96%) blood and 20/20 (100%) BM samples (Fig. 2, 
B and C). CD27 and CD70 were similarly expressed on 
blasts in blood and BM (Fig.  2, B and C). Both proteins 
were detected on AML blasts in 16/23 (70%) blood and 
19/20 (95%) BM samples (Table S1). In contrast, cells in 
the blast gate of healthy controls that mainly represent 
monocytes and basophils (Aoun and Pirruccello, 2007) did 
not express CD27 or CD70 (Fig. 2 D and Fig. S1 A). The 
AML stem/progenitor cell population that contains the dis-
ease-initiating LSCs in the majority of AML samples is a 
subfraction of CD45dimSSClo blasts characterized as lineage 
(lin)−CD90−CD34+ (Fig. S1 B; Blair et al., 1997; Bonnet 
and Dick, 1997; Sarry et al., 2011; Terwijn et al., 2014). 
Importantly, CD70 and CD27 were similarly detected on 
BM CD45dimSSCloCD34+ as well as blood CD45dimSSClo 
lin−CD90−CD34+ AML cells (Fig. 2, E–G), In contrast, BM 
HSPCs (CD45dimSSClolin−CD90+CD34+ BM cells; Majeti 
et al., 2007) from patients who underwent BM biopsy for 
other reasons than leukemia (healthy BM donors) did not 
express CD70 or CD27 (Fig. 2 H).
Because CD27 ligation leads to shedding of the 
protein (Nolte et al., 2009), FACS analysis may underes-
timate its expression. Indeed, all FACS-sorted AML blasts 
expressed CD27 and CD70 mRNAs (Fig.  3  A). In addi-
tion, CD27 and CD70 mRNA expression in blasts from 
blood and BM was 103- to 105-fold higher than in HSPCs 
from healthy BM donors (Fig.  3  B). Furthermore, CD27 
and CD70 were detected in the majority of AML cell lines 
analyzed (Fig. 3, C–E).
These results indicate that blasts and stem/progenitor 
cells of most AML patients as well as AML cell lines coexpress 
the TNF superfamily ligand–receptor pair CD70/CD27.
cd70/cd27 signaling induces stem cell signature and 
proliferation-promoting pathways in primary AML blasts
To investigate the possibility of cell-autonomous and/or 
paracrine CD70/CD27 signaling, we cultured FACS-sorted 
AML blasts from 20 different newly diagnosed patients in 
the presence of a blocking αCD70 mAb (clone 41D12-D; 
Silence et al., 2014; Riether et al., 2015) or a control mAb 
in vitro. sCD27 levels in cell supernatants were significantly 
lower in the presence of αCD70 as compared with con-
trol mAb, indicating that the CD70/CD27 interaction was 
(B) Fluidigm-based gene expression profiles in signaling pathways regulated by the CD70/CD27 interaction. Log2 fold differences of gene expression levels 
in αCD70- versus control mAb–treated blasts are shown. (C) Histogram of GO enrichment analysis of the biological pathways significantly affected in AML 
blasts treated with αCD70 mAb. (D) Gene network and canonical pathway analysis highlighting the regulation and interrelation of the most important CD70/
CD27 interaction target genes in AML blasts. (E) A publicly available microarray dataset (GSE4170) that assessed gene expression profiles during progression 
of CML was analyzed for CD70, TNIK, MSI2, and Numb using the Gene Expression Omnibus GEO2R tool. Expression values of patients in chronic-phase (n = 
42; green bars), accelerated-phase (n = 15; blue bars), and blast-phase (n = 36; red bars) CML are shown. (F) MSI2 expression in control-treated blasts from 
A–D was correlated to the sCD27 level in supernatants. Statistics: Pearson r.
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Figure 5. cd70/cd27 signaling activates Wnt signaling in AML cells and promotes symmetric cell division. (A–I) 105 U-937 cells were cultured in 
the presence of 10 µg/ml blocking αCD27 mAb or control IgG for 3 d. (A) Live cell numbers. One representative experiment of three, each run in duplicates, is 
shown. (B) BrdU incorporation on day 3 (FACS). Pooled data (n = 3) from two independent experiments are shown. (C) Intracellular localization of active β-cat-
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efficiently blocked (αCD70: 4.39 ± 0.20 U/ml; control: 
3.25 ± 0.13 U/ml; P < 0.0001). We next quantified the 
expression of 91 different stem cell signature and prolifer-
ation-promoting genes important in hematopoiesis using 
Fluidigm dynamic array (Table S2). 45 genes were differ-
entially expressed in αCD70 compared with control mAb–
treated blasts (Fig. 4 A). Hierarchical clustering revealed that 
blocking CD70/CD27 signaling down-regulated numerous 
target genes of the canonical Wnt pathway, which is essen-
tial for leukemogenesis (Fig. 4 B; Staal and Clevers, 2005). 
Moreover, the expression of important HSC and hemato-
poiesis genes, transcription factors, epigenetic modifiers, 
apoptosis, and cell cycle regulators as well as inflamma-
tory and Hedgehog-signaling genes was reduced. Of note, 
blocking CD27 signaling reduced important stem cell genes 
such as Musashi and the TNF receptor associated factor 2 
(TRAF2)– and NCK-interacting kinase (TNIK; Mahmoudi 
et al., 2009; Ito et al., 2010). In contrast, some genes related 
to Notch signaling, MAPK signaling, and matrix metallo-
proteinases were up-regulated upon blocking CD70/CD27 
signaling (Fig. 4 B). Gene ontology (GO) enrichment anal-
ysis of the differently expressed genes revealed 20 differ-
ent GO categories that were significantly regulated (over 
threefold) and established a hierarchy of pathways with cell 
proliferation, apoptosis, inflammation, and Wnt and MAPK 
signaling at the top of the hierarchy (Fig. 4 C). Furthermore, 
gene networks and canonical pathways within the 45 genes 
regulated by CD70/CD27 signaling were analyzed in silico 
using direct force analysis to study possible protein–protein 
and/or genetic interactions. This analysis revealed that stem-
ness-associated genes that were down-regulated by blocking 
CD70/CD27signaling are directly triggered by Wnt path-
way–associated genes (Fig. 4 D).
Therefore, CD70/CD27 signaling induces a stem cell 
signature at least partially via Wnt signaling, leading to a more 
undifferentiated and malignant state. Because disease evolu-
tion could not be tested in primary AML samples, we analyzed 
the expression of genes involved in the CD70/CD27 signal-
ing pathway during the evolution of indolent chronic-phase 
CML via accelerated-phase to blast-phase CML, a fatal acute 
leukemia. Using a publicly available microarray dataset (Ra-
dich et al., 2006), we found a continuous increase in CD70 
and TNIK expression from chronic- to accelerated- to blast-
phase CML. In line with Ito et al. (2010), Musashi expression 
increased, whereas expression of the cell-fate determinant 
Numb decreased during CML progression (Fig. 4 E). Cor-
respondingly, sCD27 levels in supernatants of control-treated 
AML blasts correlated with Musashi expression (Fig.  4  F). 
These data indicate that CD70/CD27 signaling is associated 
with the expression of stem cell genes such as Musashi and 
TNIK and disease progression in myeloid leukemia.
cd70/cd27 signaling regulates the cell fate of AML cells by 
activating the canonical Wnt pathway
U-937 cells express CD27 and CD70 as analyzed by FACS 
(Fig. 3 C). To functionally investigate the pathways that re-
sulted from the array analysis, we treated U-937 cells with 
blocking αCD27 or αCD70 mAb. This strongly inhibited cell 
proliferation, leading to reduced cell numbers after 3 d of 
culture (Fig.  5, A and B; and not depicted). To further in-
vestigate the effect of CD27 signaling on the Wnt pathway, 
we first determined the cellular localization of β-catenin, the 
key molecule of canonical Wnt signaling (Clevers and Nusse, 
2012). ImageStreamX analysis showed nuclear translocation 
of active β-catenin in control-treated U-937 cells, whereas 
blocking CD27 resulted in preferential cytoplasmic β-cat-
enin localization (Fig. 5, C and D). This indicates that CD27 
signaling activates the Wnt pathway and confirms the GO 
analysis of primary AML blasts. TNIK, an essential activator 
of Wnt target genes (Mahmoudi et al., 2009), colocalized 
with β-catenin (Fig.  5, C and D). Confirmative, similarity 
analysis using IDE AS software (George et al., 2006) revealed 
significantly less nuclear colocalization of β-catenin/TNIK 
in αCD27- versus control-treated cells (Fig. 5 E). This cor-
related with significantly reduced relative luminescence units 
(RLU) in a T cell transcription factor (TCF)/lymphoid en-
hancer binding factor (LEF) luciferase Wnt signaling reporter 
assay (αCD27: 1,458 ± 32 RLU; control: 616 ± 24 RLU; P = 
0.0052) and reduced transcription of the Wnt target genes 
BIRC5, CCND1, LEF, MYC, and VEGF (unpublished data). 
enin and TNIK (ImageStreamX). One representative image of n = 17,000 (αCD27) and n = 11,000 (IgG) cells is shown, respectively. (D) Percentage of cells with 
nuclear colocalization of active β-catenin/TNIK. (E) Relative similarity of DAPI and active β-catenin/TNIK. (F–H) Distribution and intensity of Numb expression 
in dividing U-937 cells (ImageStreamX). (F) Representative examples for asymmetric and symmetric cell division. (G) Percentage of asymmetric and symmetric 
cell divisions in IgG- versus αCD27-treated U-937 cells (one experiment run in triplicates; analysis of n = 353–375 dividing cells per condition). (H and I) Numb 
intensity (ImageStreamX; H) and CD11b expression (FACS) in the total U-937 cell population (I). Pooled data from two independent experiments run in duplicates. 
(J and K) FACS-sorted CD45dimSSClo blasts from the blood of n = 5 different newly diagnosed AML patients were cultured in duplicates in the presence of 10 
µg/ml αCD70 or control mAb. (J) Cells per well after 7 d (liquid culture, start: 105 cells). (K) Colonies per well after 2 wk (methylcellulose, start: 103 cells), with or 
without overnight pre-incubation with 105 irradiated (10 Gy) cells of a CD70-expressing LCL. (L and M) 103 FACS-sorted CD45dimSSClolin−CD90+CD34+ BM stem/
progenitor cells from n = 3 different healthy BM (hBM) donors were cultured in duplicates in methylcellulose in the presence of 10 µg/ml αCD70 or control mAb. 
Colonies (L) and cells per well (M) were enumerated after 2 wk. (N–P) 105 FACS-sorted CD45dimSSClo blasts from the blood of n = 5 different newly diagnosed 
AML patients were cultured in liquid culture for 7 d in the presence of 10 µg/ml αCD70 or control mAb. Numb intensity (ImageStreamX; N), expression of CD11b 
(FACS; O), and percentage (P) of asymmetric and symmetric cell divisions in the total cell population (analysis of n = 61–201 dividing cells per condition per 
patient sample). Data are shown as mean ± SEM. Statistics: (A) two-way ANO VA; (B, D, E, G–J, and L–P) t test; and (K) one-way ANO VA. *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001. Bars, 10 µm. adv., adverse; ctrl, control; int., intermediate; MFI, mean fluorescence intensity. 
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Figure 6. the cd70/cd27 interaction activates Wnt signaling in AML cells via trAF2 and tnIK. (A and B) 105 U-937 cells stably expressing shRNA 
against TRAF2 (shTRAF2; A) or TNIK (shTNIK; B) were cultured in duplicates with 10 µg/ml blocking αCD27 mAb or control IgG for 3 d. Untreated and scrRNA- 
expressing cells were used as controls. Live cells were enumerated daily. (B) One representative of two independent experiments is shown. (C and D) 105 
scr- and shTNIK-transduced U-937 cells were cultured in triplicates in the presence of IgG or αCD27 mAb. Percentage of asymmetric and symmetric cell 
divisions (analysis of n = 84–161 dividing cells per condition; C) and Numb intensity in the total cell population (D) are shown. (E) Kaplan-Meier survival 
curves of NSG mice xenotransplanted i.v. with 105 scr- or shTNIK-transduced U-937 cells. (F–J) CD27 (shCD27), TRAF2, or TNIK were stably knocked down 
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Interestingly, blocking the CD70/CD27 interaction resulted 
in a higher percentage of asymmetrically dividing U-937 
cells, as analyzed by the intracellular distribution of the cell-
fate determinant Numb (Fig. 5, F and G; Wu et al., 2007; Ito 
et al., 2010; Zimdahl et al., 2014). As a consequence, blocking 
CD70/CD27 signaling resulted in increased amounts of in-
tracellular Numb and surface CD11b (Fig. 5, H and I), indi-
cating cell differentiation.
In FACS-sorted blasts from different AML patients, 
αCD70 treatment resulted in significantly reduced cell num-
bers in liquid cultures (Fig.  5  J) and colony formation in 
methylcellulose (Fig. 5 K), confirming the results observed in 
U-937 cells. Moreover, preincubation of AML blasts with an 
irradiated CD70-expressing lymphoblastoid B cell line (LCL; 
Ochsenbein et al., 2004) did not significantly increase colony 
formation, suggesting that CD70/CD27 interactions in AML 
blasts are already maximal (Fig. 5 K). In contrast and in line 
with our previous work (Riether et al., 2015), αCD70 treat-
ment did not affect colony formation of HSPCs from healthy 
BM donors (Fig. 5, L and M). We observed elevated Numb 
protein levels and a significantly increased expression of the 
differentiation marker CD11b in AML blasts after αCD70 
treatment, whereas CD14 and CD33 expression remained un-
changed (Fig. 5, N and O; and not depicted). Control-treated 
blasts divided significantly more often symmetrically than 
asymmetrically. Blocking CD70 reversed this balance in all 
patient samples and significantly increased asymmetric over 
symmetric cell divisions (Fig. 5 P).
Together, these results indicate that the CD70/CD27 
interaction in AML blasts promotes symmetric cell division, 
resulting in more undifferentiated stem-like cells.
cd27 signaling regulates cell fate 
decision via trAF2 and tnIK
To investigate whether CD27 signaling regulates AML cell 
fate via TRAF2 and TNIK (Schürch et al., 2012), we knocked 
down these CD27 downstream molecules in U-937 cells 
using shRNA. TRAF2 or TNIK knockdown reduced U-937 
cell growth to a similar extent as αCD27 treatment. Inter-
estingly, αCD27 treatment of TRAF2 or TNIK knockdown 
cells did not further decrease cell growth (Fig. 6, A and B). 
Similarly to blocking CD27 signaling (Fig. 5, G and H), TNIK 
knockdown promoted asymmetric cell division and increased 
Numb expression in the U-937 cell population, which could 
not be further enhanced by adding αCD27 mAb (Fig. 6, C 
and D). Moreover, stable knockdown of TNIK in U-937 cells 
significantly prolonged survival of xenotransplanted NOD/
LtSz-scid IL-2Rγnull (NSG) mice (Fig.  6  E). This suggests 
that CD27 signaling increases symmetric AML cell division 
via TRAF2/TNIK signaling.
To further elaborate on these findings in a more physi-
ological setting, we knocked down CD27, TRAF2, or TNIK 
in primary AML blasts. Knockdown efficiency and specific-
ity were assessed on mRNA and protein level by quantita-
tive real-time PCR (qRT-PCR) and ImageStreamX analysis, 
respectively (Fig. 6 F and not depicted). TNIK knockdown 
decreased Wnt target gene expression (Fig. 6 G), and CD27, 
TRAF2, or TNIK knockdowns reduced colony formation 
in methylcellulose (Fig.  6  H). Importantly, this reduction 
was similar between blasts with CD27, TRAF2, or TNIK 
knockdown and was maintained during serial replating. In 
contrast, cell numbers per well were considerably increased 
in knockdown cells during the first round of plating but 
significantly declined in further rounds, indicating that 
CD27, TRAF2, or TNIK knockdown induced differentia-
tion, repressed self-renewal, and led to exhaustion of these 
cells (Fig. 6 I). As expected, the addition of αCD70 mAb to 
TNIK knockdown AML blasts did not further reduce col-
ony formation (Fig. 6 J).
These results indicate that Wnt-activating and stem-
ness-maintaining CD27 signals are mainly mediated via 
TRAF2 and TNIK in AML cells.
Blocking the cd70/cd27 interaction in AML stem/
progenitor cells inhibits cell growth and colony formation 
and induces differentiation
FACS-sorted CD45dimSSClolin−CD90−CD34+ AML stem/
progenitor cells from blood of six patients from different cy-
togenetic/molecular risk groups were cultured in the pres-
ence of blocking αCD70 or control mAb. After 3 d, cells were 
enumerated, and sCD27 levels were determined in superna-
tants. Blocking CD70 significantly reduced cell numbers per 
well and sCD27 levels in supernatants (Fig. 7, A and B). Im-
portantly, sCD27 levels were also reduced when adjusted for 
different cell numbers (Fig. 7 C). To assess colony-forming 
capacity, AML stem/progenitor cells were cultured in meth-
ylcellulose in the presence of blocking αCD70 or control 
mAb. In line with our results from blasts (Fig. 6 J), αCD70 
treatment significantly reduced colony formation from AML 
stem/progenitor cells (Fig. 7 D). Serial replating experiments 
revealed that this effect was maintained even in the absence 
of αCD70 mAb in the primary or secondary replating cul-
in FACS-sorted CD45dimSSClo blasts from the blood of patient 142. Scr-transduced blasts were used as controls. (F) Knockdown efficiency and specificity 
were assessed by quantifying CD27, TRAF2, and TNIK mRNA (qRT-PCR). Data are shown as fold expression of scr (=1). (G) Wnt target gene expression after 
TNIK knockdown (qRT-PCR). (H and I) Duplicates of 103 shCD27, shTRAF2, shTNIK, and scr blasts were cultured in methylcellulose, and colonies (H) and cells 
per well (I) were enumerated after 2 wk (1° plating). 5 × 103 cells were then replated, and colonies and cells were assessed 2 wk later (first replating). This 
was repeated one more time (second replating). (H and I) Percentages of knockdown versus scr blasts are shown. (J) Duplicates of 103 shTNIK and scr blasts 
were cultured in methylcellulose in the presence of 10 µg/ml αCD70 or control mAb, and colonies were enumerated after 2 wk. Data are shown as mean ± 
SEM. Statistics: (A, B, H, and I) two-way ANO VA; (C, D, and J) one-way ANO VA; and (E) log-rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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tures (Fig. 7, D and E). In addition, the expression of the dif-
ferentiation-inducing genes RUNX1, SPI1 (PU.1), CEBPα, 
CEBPβ, and ID1 (Rosenbauer and Tenen, 2007) was sig-
nificantly increased in AML stem/progenitor cells cultured 
overnight in the presence of blocking αCD70 compared with 
control mAb (Fig. 7 F).
These findings indicate that blocking the CD70/CD27 
interaction reduces AML stem/progenitor cell numbers and 
induces differentiation.
Blocking the cd70/cd27 interaction prolongs survival in 
AML xenotransplantation models
U-937 cells or FACS-sorted blasts from two different AML 
patients were injected i.v. into sublethally irradiated NSG 
mice. After 7 d of engraftment, NSG mice were random-
ized to αCD70 or control mAb treatment. αCD70 treatment 
significantly prolonged survival in xenotransplanted mice 
(Fig.  8, A–C). Similarly, stable TNIK knockdown in AML 
blasts prolonged survival of xenotransplanted mice (Fig. 8 D).
Figure 7. Blocking the cd70/cd27 interaction in AML stem/progenitor cells inhibits cell growth and colony formation and induces differen-
tiation. (A–C) Duplicates of 105 FACS-sorted CD45dimSSClolin−CD90−CD34+ stem/progenitor cells from blood of six different AML patients were cultured 
in liquid culture in the presence of 10 µg/ml αCD70 or control mAb for 3 d. (A and B) Cell numbers per well (A) and sCD27 levels (B) in supernatants were 
determined. (C) Levels of sCD27 per live cell after 3 d of culture were calculated. (D and E) 103 FACS-sorted CD45dimSSClolin−CD90−CD34+ stem/progenitor 
cells from blood of three different AML patients were cultured in duplicates overnight in liquid medium in 96-well plates in the presence of 10 µg/ml 
αCD70 or control mAb. Cells were then plated into methylcellulose in the presence of 10 µg/ml αCD70 or control mAb for 2 wk (1° plating). 104 cells were 
then replated into methylcellulose without mAbs, and colonies and cell numbers were assessed 2 wk later (first replating). This was repeated one more 
time (second replating). (E) Fold reduction of colony formation by αCD70 mAb in primary plating and replating (pooled data from D). (F) 105 FACS-sorted 
CD45dimSSClolin−CD90−CD34+ AML stem/progenitor cells from the patients from A–C were cultured overnight in liquid culture in the presence of 10 µg/ml 
αCD70 or control mAb, and the expression of RUNX1, CEB PA, CEB PB, SPI1 (PU.1), and ID1 mRNA was analyzed (qRT-PCR, pooled data from two independent 
experiments). Data are shown as mean ± SEM. Statistics: (A–D and F) Student’s t test; (E) one-sample Student’s t test (1°) and one-way ANO VA (1° vs. first/
second replating). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. adv., adverse; ctrl, control; fav., favorable; int., intermediate.
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Figure 8. Blocking cd70 promotes differentiation of xenotransplanted AML blasts and prolongs survival. (A–C) Kaplan-Meier survival curves of 
NSG mice xenotransplanted i.v. with 105 U-937 cells (A) or 106 FACS-sorted CD45dimSSClo blasts (B and C) from the blood of patients (Pat) 142 and 145, 
respectively. Mice were treated with 10 mg/kg αCD70 or control (ctrl) mAb every third day starting 7 d after transplantation. (D) Kaplan-Meier survival 
curves of NSG mice xenotransplanted i.v. with 106 FACS-sorted CD45dimSSClo blasts from patient 142. Before transplantation, stable knockdown of TNIK 
was established. Scr-transduced cells were used as controls. (E) sCD27 was quantified in the serum of NSG mice from B and C at different time points. 
(F and G) 106 FACS-sorted CD45dimSSClo blasts from patient 142 were xenotransplanted into NSG mice. Mice were treated as described for A–C. 40 d after 
transplantation, mice were sacrificed, and total numbers of human CD45+ AML cells (F) and CD45+CD34+ AML stem/progenitor cells (G) in the BM were 
quantified (FACS). (H–M) Human CD45+CD34+ AML stem/progenitor cells were purified by FACS sorting. Numb intensity was analyzed by ImageStreamX (H), 
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Human sCD27 was present in the sera of NSG mice 
xenografted with primary AML samples, and its levels in-
creased as the disease progressed. Interestingly, in αCD70-
treated mice, human sCD27 levels were significantly lower 
than in controls, indicating that CD70 blockade specifically 
reduced CD27 signaling on human AML blasts in these 
mice (Fig. 8 E). αCD70 treatment significantly reduced total 
human CD45+ cells and CD45+CD34+ AML stem/progeni-
tor cells in xenografted mice 40 d after transplantation (Fig. 8, 
F and G). Importantly, Numb expression was increased in the 
population of CD45+CD34+ AML stem/progenitor cells, in-
dicating a more differentiated state (Fig. 8 H). Furthermore, 
FACS-sorted CD45+CD34+ AML stem/progenitor cells from 
αCD70-treated xenografted mice down-regulated the expres-
sion of several Wnt signaling–, hematopoiesis-, and inflamma-
tion-associated genes (Fig. 8 I) and formed significantly fewer 
colonies in methylcellulose per well than controls (Fig. 8 J). 
Similarly, the CFUs of sorted CD45+CD34+ AML stem/pro-
genitor cells per mouse were significantly reduced by αCD70 
treatment (Fig. 8 K). In contrast, cell numbers per well and 
per colony were considerably increased (Fig. 8, L and M).
Together, these data suggest that αCD70 treatment of 
xenografted mice prolonged survival by inducing differentia-
tion of AML stem/progenitor cells.
Blocking the cd70/cd27 interaction reduces stem cell 
gene expression, induces differentiation, and inhibits self-
renewal in AML stem/progenitor cells
To confirm and extend these findings, we performed xeno-
grafts with additional patient samples from each risk group. 
Two weeks after transplantation, NSG mice were randomized 
and treated for 2 wk with αCD70 or control mAb. αCD70 
treatment did not affect total BM cell numbers (Fig.  9 A). 
In contrast, human CD45dimSSClo blasts and CD45dimSSClo 
lin−CD90−CD34+ AML stem/progenitor cells in BM were 
significantly reduced, irrespective of the cytogenetic/molec-
ular risk group of the transplant (Fig. 9, B–D). Importantly, 
αCD70 treatment induced a significant up-regulation of 
CD27 on CD45dimSSClolin−CD90−CD34+ AML stem/pro-
genitor cells (Fig. 9 E). In addition, αCD70 treatment resulted 
in a trend of CD11b and Numb up-regulation in human 
CD45dimSSClo AML blasts from xenografts (Fig. 9, F and G). 
Furthermore, FACS-sorted CD45dimSSClolin−CD90−CD34+ 
AML stem/progenitor cells from αCD70-treated mice 
formed significantly fewer colonies in methylcellulose per 
well than controls (Fig. 9 H). In contrast, cell numbers per 
colony were considerably increased (Fig.  9  I). Importantly, 
Fluidigm dynamic array analysis of ex vivo FACS-sorted 
human CD45dimSSClolin−CD90−CD34+ AML stem/pro-
genitor cells from xenografts revealed that αCD70 treatment 
resulted in a down-regulation of important stem cell– and he-
matopoiesis-associated genes (Fig. 9, J and K), confirming and 
extending our in vitro data from AML blasts (Fig. 4, A and B).
To confirm the reduction of AML stem/progenitor 
cell numbers in vivo, we performed secondary transplanta-
tions using whole BM cells from primary xenotransplanted 
NSG mice. NSG mice receiving BM cells from αCD70-
treated primary xenografts survived significantly longer than 
NSG mice transplanted with BM cells from control mAb-
treated primary xenografts (Fig. 10, A–D). Importantly, this 
effect was found in samples from all different cytogenetic/
molecular risk groups.
These results indicate that blocking CD70/CD27 sig-
naling reduces numbers and function and induces differen-
tiation of AML stem/progenitor cells by inhibiting stem cell 
gene expression programs.
dIScuSSIon
An undifferentiated malignant state is a hallmark of AML 
blasts that is maintained by cell-intrinsic signals, but also pos-
sibly regulated by cell-extrinsic cues (Bajaj et al., 2015). In this 
study, we document an unexpected role for the CD70/CD27 
ligand–receptor pair in the induction of Wnt signaling and 
stem cell gene signatures in AML. To our knowledge, this is 
the first report showing that the interaction of a TNF super-
family ligand–receptor pair induces stemness in cancer cells.
First, we focused on cells in the CD45dimSSClo gate that 
identifies blasts in different AML types (Borowitz et al., 1993; 
Kroft and Karandikar, 2007; Gorczyca, 2010). Using sensitive 
xenograft assays, Sarry et al. (2011) have identified hetero-
geneous AML LSCs in bulk leukemia samples in fractions 
different from the originally reported lin−CD34+CD38− 
population, even in cells expressing differentiation markers 
(Bonnet and Dick, 1997). Because stem cell gene signature 
profiles have been documented in bulk blast populations in 
AML (Gentles et al., 2010; Eppert et al., 2011), it has been 
suggested that differentiated blasts may exhibit plasticity and 
reenter the LSC state (Kreso and Dick, 2014). We then ex-
tended our analyses to lin−CD90−CD34+ cells, a subfraction 
of CD45dimSSClo cells that contains the disease-initiating 
LSCs in the majority of AML samples (Blair et al., 1997; 
Terwijn et al., 2014). Importantly, CD70/CD27 signaling 
induced stemness in AML blasts and in phenotypically de-
fined stem/progenitor cells.
Stem cells can self-renew either by symmetric renewal 
leading to an expansion of the stem cell pool or by asym-
metric division, by which the pool remains constant (Wu et 
al., 2007). Stem cell gene signatures predict therapy resistance 
the expression of selected Wnt signaling and HSC genes were quantified by qRT-PCR (I), and 103 cells were plated into methylcellulose for colony analysis 
(J–M). Colonies of human CD45+CD34+ AML stem/progenitor cells per well were enumerated (J), and total CFUs per mouse were calculated (K). Cells per well 
were enumerated (L), and cells per colony were calculated (M). Statistics: (A–D) log-rank test; (E–H and J–M) Student’s t test. *, P < 0.05; **, P < 0.01; ***, 
P < 0.001; ****, P < 0.0001. int., intermediate. 
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Figure 9. Blocking the cd70/cd27 interaction inhibits stem cell gene expression and induces differentiation in AML stem/progenitor cells. 106 
FACS-sorted CD45dimSSClo blasts from the blood of three different AML patients were injected i.v. into NSG mice (n = 3 mice per risk group per condition). 
After 2 wk of engraftment, mice were randomized and treated with 10 mg/kg αCD70 or control (ctrl) mAb every third day for 2 wk. (A–D) Total BM cell 
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and aggressive disease and negatively correlate with survival 
in AML and other malignancies (Ben-Porath et al., 2008; 
Gentles et al., 2010; Eppert et al., 2011; Metzeler et al., 2013). 
Mechanistically, stem cell determinants such as stemness- 
associated genetic signatures (Gentles et al., 2010; Eppert et al., 
2011; Metzeler et al., 2013) and epigenetic profiles (Figueroa 
et al., 2010; Bartholdy et al., 2014) often oppose differenti-
ation-inducing programs in AML blasts, leading to a block 
in terminal differentiation and senescence (Tenen, 2003). 
Currently, all-trans retinoic acid is the only approved drug 
that induces differentiation in blasts of acute promyelocytic 
leukemia (Grimwade et al., 2010), but other differentiation- 
inducing agents for AML are under investigation (Nowak 
et al., 2009). We now show that blocking the CD70/CD27 
interaction shifted the balance from symmetric self-renewal 
to asymmetric cell division. This reduced the pool of AML 
stem/progenitor cells, leading to more differentiated leukemia 
cells, as documented by increased expression of the cell fate 
determinant Numb and the differentiation marker CD11b.
The canonical Wnt pathway, which is central for HSC 
development and maintenance, is constitutively active in my-
eloid leukemia and of crucial importance for LSCs (Staal 
and Clevers, 2005; Wang et al., 2010; Heidel et al., 2012). 
Self-renewal and β-catenin signatures in murine and human 
AML LSCs are often induced by translocations involving 
the mixed lineage leukemia gene family (Krivtsov and Arm-
strong, 2007). In our study, the CD70/CD27 interaction ac-
tivated Wnt signaling in AML cells. However, CD70/CD27 
signaling triggers additional survival-inducing and prolifer-
ation-promoting pathways, such as the canonical and non-
canonical NF-κB pathways and the JNK pathway (Nolte et 
al., 2009). Importantly, canonical NF-κB signaling enhances 
Wnt signaling, and the interplay of the NF-κB and Wnt path-
ways induces stem cell-like and tumor-initiating capacities in 
non–stem cells (Schwitalla et al., 2013). Interestingly, blocking 
CD70/CD27 signaling reduced the expression of Musashi, an 
RNA binding protein and Numb repressor. Genetic deletion 
of Musashi in a mouse model of blast-phase CML signifi-
numbers (A), the frequency and total numbers of human CD45dimSSClo AML cells (B and C), and total numbers of human CD45dimSSClolin−CD90−CD34+ AML 
stem/progenitor cells (D) in the BM were quantified (FACS). (E) Mean fluorescence intensity (MFI) quotients of CD27 versus isotype on human CD45dimSSClo 
lin−CD90−CD34+ AML stem/progenitor cells in the BM (FACS). (F and G) CD11b expression (FACS; F) and Numb intensity (ImageStreamX; G) was determined 
ex vivo in human CD45dimSSClo AML blasts (each data point represents pooled cells from n = 3 mice). (H and I) 103 FACS-sorted human CD45dimSSClo 
lin−CD90−CD34+ AML stem/progenitor cells were cultured in methylcellulose. Colony formation (H) and cell numbers per colony (I) were determined after 
2 wk. (A–I) Horizontal lines indicate mean. (J and K) 5 × 103 to 106 human CD45dimSSClolin−CD90−CD34+ AML stem/progenitor cells were FACS-sorted ex 
vivo from αCD70 or control mAb-treated NSG mice and subjected to mRNA analysis using Fluidigm dynamic array. (J) Heat maps of differentially expressed 
genes in human AML stem/progenitor cells from individual mice. (K) Gene expression profiles in signaling pathways in human AML stem/progenitor cells 
regulated by the CD70/CD27 interaction. Log2 fold differences of gene expression levels in signaling pathways (pooled data from all mice in K). Statistics: 
(A–E, H, and I: unpaired; F and G: paired) Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. adv., adverse; fav., favorable; int., intermediate.
Figure 10. Blocking the cd70/cd27 in-
teraction in primary xenografts prolongs 
survival in secondarily transplanted nSG 
mice. (A–D) Primary xenotransplants were 
established by i.v. injection of 106 FACS-sorted 
CD45dimSSClo blasts from the blood of patients 
(Pat) 142, 161, 163, and 167, respectively, 
into NSG mice. After engraftment, mice were 
treated with 10 mg/kg αCD70 or control (ctrl) 
mAb every third day. Treatment was started 
2 wk after transplantation, and mice were 
treated for 2 wk (A, C, and D) or started 7 
d after transplantation (B), and mice were 
treated for 33 d. Then, 5 × 106 (A, C, and D) or 
107 whole BM cells (B) from primary animals 
were injected i.v. into secondary NSG mice. 
Secondary recipients were left untreated, and 
Kaplan-Meier survival curves are shown. (A) 
Patient 163, favorable (fav.) risk group. (B and 
C) Patients 142 and 165, intermediate (int.) 
risk group, respectively. (D) Patient 161, ad-
verse (adv.) risk group. Statistics: log-rank test. 
*, P < 0.05; **, P < 0.01. 
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cantly reduced leukemia progression (Ito et al., 2010). Earlier 
results suggested that Musashi might impair asymmetric di-
vision and arrest differentiation, partially through suppression 
of Numb (Imai et al., 2001). The canonical Wnt pathway reg-
ulates the expression of Musashi in intestinal epithelial stem 
cells through a mechanism involving a functional TCF/LEF 
binding site on its promoter (Rezza et al., 2010). Therefore, it 
is likely that CD70/CD27 signaling indirectly regulates Mu-
sashi via the Wnt pathway.
sCD27 is an important indicator for the CD27/CD70 
interaction in vivo. Human sCD27 increased in the AML 
xenotransplant mice during disease progression, indicating 
that sCD27 levels represent the strength of CD27 ligation 
on AML blasts. Importantly, the level of sCD27 in sera of 
AML patients is an independent negative prognostic factor 
for overall survival. Serum sCD27 could therefore be used 
clinically as a surrogate biomarker to address the stemness sig-
nature of a patient’s AML blasts and to predict outcome. Most 
likely, CD27 is engaged by CD70 cross-presented by other 
AML blasts or stem/progenitor cells in a paracrine manner. 
Alternatively, autocrine CD70/CD27 signaling occurs within 
the membrane of the same malignant cell. In addition, ac-
tivated CD70-expressing lymphocytes may trigger CD27 
on AML blasts or stem/progenitor cells. Importantly, the 
CD70/CD27 interaction can be blocked using mAb, leading 
to prolonged survival in primary and secondary xenotrans-
plantation models. Because αCD70 treatment is specific for 
malignant cells and does not affect healthy HSPCs, blocking 
the CD70/CD27 interaction may represent a promising ther-
apeutic strategy for AML.
MAterIALS And MethodS
Mice
NSG mice were a gift from J. Schwaller (Department of Bio-
medicine, University Hospital of Basel, Basel, Switzerland) 
and have been previously described (Shultz et al., 2005). Mice 
were housed under specific pathogen–free conditions in indi-
vidually ventilated cages with food and water ad libitum and 
were regularly monitored for pathogens. Animal experiments 
were approved by the local experimental animal committee 
of the Canton of Bern and performed according to Swiss 
laws for animal protection.
cell lines
The human leukemia cell lines Kasumi-1 (Asou et al., 1991), 
HL-60 (Gallagher et al., 1979), PL-21 (Kubonishi et al., 
1984), NB4 (Lanotte et al., 1991), HT-93 (Kishi et al., 1998), 
U-937 (Sundström and Nilsson, 1976), MV4-11 (Lange et al., 
1987), MOLM-13 (Matsuo et al., 1997), NOMO-1 (Kato et 
al., 1986), KG-1 (Koeffler and Golde, 1978), and HEL (Mar-
tin and Papayannopoulou, 1982) have been described before.
Patients and controls
Peripheral blood samples (n = 42; patient age: 59.9 ± 2.1 
yr; morphological blast count: 66.5 ± 2.8%), serum sam-
ples (n = 137; patient age: 58.8 ± 1.2 yr; blood leukocyte 
count: 30.6 ± 4.7 G/liter), and BM aspirates (n = 25; patient 
age: 57.9 ± 3.6 yr; morphological blast infiltration: 72.2 ± 
3.9%) were obtained from untreated AML patients at diag-
nosis at the University Hospital of Bern (Bern, Switzerland) 
after written informed consent. Study data were collected 
and managed using REDCap electronic data capture tools 
hosted at the Department of Clinical Research (Harris et 
al., 2009). Serum samples were predominantly from a retro-
spective cohort (2011–2014). Blood, BM, and correspond-
ing serum samples were collected prospectively (2013–2016). 
Detailed patient and control donor characteristics are listed 
in Table S1. Peripheral blood samples (n = 8; age 29.4 ± 1.8 
yr) and serum samples (n = 5; age: 30.6 ± 2.1 yr) from young 
healthy individuals, serum samples (n = 10; age: 68.7 ± 2.2 
yr) from elderly healthy donors, as well as BM samples from 
patients who underwent BM biopsy for reasons other than 
leukemia (n = 3; age: 73.3 ± 6.4 yr) were used as controls. 
Analysis of samples was approved by the local ethical commit-
tee of the Canton of Bern.
Antibodies, flow cytometry, and cell purification
αCD27-FITC (clone LG.7F9), αCD27-allophycocyanin 
(APC)-Cy7 (clone LG.3A10), Armenian hamster IgG-FITC 
and -APC-Cy7 (clone HTK88), αCD11b-PE-Cy7 (clone 
M1/70), rat IgG 2bκ-PE-Cy7 (clone RTK4530), αCD34-
APC (clone 561), αCD45–Pacific Blue (clone HI30), αCD33-
PerCP-Cy5.5 (clone WM53), αCD90-PerCP-Cy5.5 (clone 
5E10), and anti–mouse CD45-PE-Cy7 (clone 30-F11) were 
from BioLegend. Lineage-positive cells were excluded by 
staining using biotinylated αCD2 (clone RPA2.10), αCD3 
(clone OKT39), αCD14 (clone HCD14), αCD16 (clone 
3G8), αCD19 (clone HIB19), αCD56 (clone HCD56), 
and αCD235 (clone HIR2; BioLegend), followed by a sec-
ond step using streptavidin–Horizon-V500 (BD). αBrdU-
APC was from BD. Human αCD70 (clone 41D12-D) and 
a corresponding control mAb specific for the F protein of 
respiratory syncytial virus (palivizumab [Synagis]; Astra-
Zeneca) were kindly provided by arGEN-X. CD70 stain-
ings were performed by incubation with 50 µg/ml αCD70 
mAb or control mAb followed by a second step using anti–
human FC-PE (BioLegend).
Samples were acquired on an LSR II (BD), and sorting 
procedures were conducted using an FAC SAria (BD). Data 
were analyzed using FlowJo software (Tree Star).
Antibodies and reagents for treatment
Human αCD27 (clone 1A4) and the corresponding iso-
type control (clone 15H6) were from Beckman Coulter. 
Human αCD70 (clone 41D12-D) and palivizumab (Syn-
agis) were from arGEN-X.
Analysis of cell growth
105 cells of AML cell lines were seeded into 24-well tis-
sue culture plates and cultured in the presence of 10 µg/ml 
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blocking αCD27 or αCD70 mAb or the respective control 
mAb. Live cell numbers were counted daily using a Neubauer 
chamber and trypan blue exclusion.
Murine xenograft AML model and 
secondary transplantations
Xenotransplantations were performed as previously described 
(Sanchez et al., 2009). In brief, NSG mice were sublethally ir-
radiated (2.75 Gy) on the day before injection. 106 FACS-pu-
rified CD45dimSSClo blasts from the peripheral blood or BM 
of newly diagnosed AML patients (patients 142, 145, 161, 
162, 163, 164, 167, and 168; Table S1) were injected i.v. into 
the tail vein. Starting 1–2 wk after transplantation, mice were 
randomized, and 10 mg/kg αCD70 mAb (41D12-D) or con-
trol mAb was administered i.p. every third day. Mice were 
monitored daily for signs of morbidity (significant weight 
loss, failure to groom, abnormal gait, and posture) and euth-
anized when terminally ill. Secondary transplantations were 
performed by injecting 5 × 106 or 107 whole BM cells from 
primary xenografted animals i.v. into sublethally irradiated 
(2.75 Gy, day before transplantation) NSG mice.
Liquid cultures and colony assays
In vitro liquid cultures and methylcellulose colony assays 
of FACS-purified CD45dimSSClo blasts from blood or BM 
and CD45dimSSClolin−CD90−CD34+ AML stem/progenitor 
cells from blood of newly diagnosed AML patients (blasts: 
patients 38, 39, 72, 139, 142, 143, 145, and 146; CD45dim 
SSClolin−CD90−CD34+ AML stem/progenitor cells: patients 
161, 162, 163, 164, 167, and 168; Table S1) were performed 
as described (Schürch et al., 2013), with slight modifications. 
Starting cell numbers were 105 for liquid cultures and 103 for 
colonies, respectively. 10 µg/ml αCD70 or control mAb were 
added to the cultures in the first round of plating (1°). For 
each round of serial colony replating (first and second replat-
ing), total cells were collected from the methylcellulose, and 
5 × 103 cells were replated into methylcellulose without any 
treatment. Colony numbers were assessed by inverted light 
microscopy after 2 wk for each round of plating. In one ex-
periment, AML blasts were preincubated overnight with 105 
irradiated (10 Gy) cells of a CD70-expressing LCL (Ochsen-
bein et al., 2004), followed by plating in methylcellulose.
Analysis of proliferation in vitro
U-937 cells were cultured in vitro for 72  h, and BrdU 
(10 µM) was added for the last 4 h of culture. BrdU staining 
was performed using the APC BrdU Flow kit (BD) according 
to the manufacturer’s instructions.
Lentiviral tcF/LeF reporter assay
U-937 cells were transfected with TCF/LEF lentiviral parti-
cles expressing firefly luciferase or the respective positive and 
negative control lentiviral particles (Cignal Lenti TCF/LEF 
reporter [luc] kit; SABiosciences) at a multiplicity of infec-
tion of 10, in the presence of 8 µg/ml SureEntry transduction 
reagent (SABiosciences) according to the manufacturer’s in-
structions. Stable cell lines were generated under puromycin 
selection (2.5 µg/ml; Santa Cruz Biotechnology, Inc.). Lu-
ciferase activity was measured on an Infinite 200 microplate 
reader (Tecan) using the Steady-Glo Luciferase Assay System 
(Promega) according to the manufacturer’s instructions.
qrt-Pcr
For qRT-PCR, total RNA was extracted using the RNeasy 
Mini kit (QIA GEN). Complementary DNA synthesis was 
performed using the High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems). Gene expression analy-
sis was performed using TaqMan Gene Expression Assays 
for CD27, CD70, TNIK, CCND1, BIRC5, TRAF2, LEF, 
MYC, VEGF, and GAP DH (Applied Biosystems), as well as 
using self-designed primers for CEB PA, CEB PB, RUNX1, 
ID1, SPI1 (PU.1), and GAP DH (Table S2) using SYBR green 
reaction (Applied Biosystems). qRT-PCR reactions were per-
formed in triplicates including nontemplate controls using 
an ABI Prism 7500 Sequence Detection System (Applied 
Biosystems). Relative quantification of gene expression was 
normalized against a reference gene (GAP DH) and calculated 
as an exponent of 2 (2ΔCt).
tnIK and β-catenin stainings
AML cells were fixed with 4% paraformaldehyde, followed 
by blocking and permeabilization with 5% goat serum/1% 
bovine serum albumin in 0.1% PBS–Tween 20 for 1  h in 
FACS tubes. After washing, cells were incubated for 1 h with 
mouse anti–active β-catenin (dilution 1:100; clone 8E7; 
EMD Millipore) and rabbit αTNIK antibody (dilution 1:50; 
D-16; Santa Cruz Biotechnology, Inc.), followed by incuba-
tion with anti–mouse IgG–Alexa Fluor 546 (dilution 1:500; 
Invitrogen) and goat anti–rabbit IgG–Alexa-Fluor 488 (dilu-
tion: 1:1,000; Cell Signaling Technology) for 30 min. Nuclei 
were stained with 10 µg/ml DAPI. Cells were acquired on 
an ImageStreamX Mark II imaging flow cytometer (Amnis/
EMD Millipore) and analyzed using INS PIRE and IDE AS 
software (Amnis/EMD Millipore).
numb staining and analysis of symmetric versus 
asymmetric cell division
AML cells were fixed with 4% paraformaldehyde, permea-
bilized with 1× wash buffer (Dako), and blocked with 10% 
normal goat serum (Invitrogen) in wash buffer (Dako). Cells 
were incubated overnight at 4°C with the primary rabbit 
αNumb antibody (ab14140; Abcam) diluted 1:50 in diluent 
(Dako). Incubation with the secondary antibody, goat anti–
rabbit IgG–Alexa Fluor 568 (dilution 1:1,000; Abcam), was 
performed for 1 h at room temperature. DAPI (Roche) was 
used to counterstain for DNA. Samples were acquired on an 
ImageStreamX Mark II imaging flow cytometer and analyzed 
using INS PIRE and IDE AS software. Dividing cells were an-
alyzed by IDE AS software in a blinded fashion by two inde-
pendent researchers. A difference in Numb intensity between 
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daughter cells of at least 1.8-fold was defined as asymmetric 
cell division according to Zimdahl et al. (2014).
Knockdown of cd27, trAF2, and tnIK
CD27, TRAF2, or TNIK was silenced in AML cells using 
transduction-ready viral particles for gene silencing (Santa 
Cruz Biotechnology, Inc.). In brief, 5 × 104 cells were trans-
duced overnight at 37°C and 5% CO2 with 2 × 105 infectious 
units of shCD27, shTRAF2, or shTNIK lentiviral particles or 
control scrambled (scr) RNA lentiviral particles (Santa Cruz 
Biotechnology, Inc.) in the presence of 5 µg/ml polybrene 
(Sigma-Aldrich) according to the manufacturer’s instructions. 
After 18  h, medium was removed, and cells were cultured 
in medium supplemented with 2.5 µg/ml puromycin (Santa 
Cruz Biotechnology, Inc.) to select for stable expression of 
shRNA or scrRNA. After selection, cells were cultured in 
medium without antibiotics.
determination of scd27 in serum and 
cell culture supernatants
Human sCD27 in serum samples from newly diagnosed, 
untreated AML patients, young and elderly healthy controls, 
and in serum from xenotransplanted NSG mice was mea-
sured using the PeliKine Compact human soluble CD27 
ELI SA kit according to the manufacturer’s instructions (San-
quin). For determination of sCD27 in cell culture superna-
tants, 105 FACS-sorted CD45dimSSCloCD33+ AML blasts or 
CD45dimSSClolin−CD90−CD34+ AML stem/progenitor cells 
were cultured in liquid culture in 96-well V-bottom plates 
in the presence of 10 µg/ml αCD70 or control mAb for 
3 d. sCD27 in supernatants was measured using the PeliKine 
Compact human soluble CD27 ELI SA kit.
Gene expression profiling using Fluidigm dynamic array
105 FACS-sorted CD45dimSSCloCD33+ blasts from the 
blood or BM of 20 different newly diagnosed AML patients 
were cultured in vitro in the presence of αCD70 or control 
mAb for 72 h, or CD45+lin−CD90−CD34+ AML stem/pro-
genitor cells were FACS-sorted ex vivo from αCD70- or 
control mAb–treated NSG mice. Cells were subjected to 
simultaneous isolation of DNA, RNA, and proteins using 
the AllPrep DNA/RNA/Protein Mini kit (QIA GEN) ac-
cording to an optimized protocol (Radpour et al., 2009, 
2011). The quantity of extracted molecules was assessed by 
spectrophotometry using a NanoDrop ND-1000 (Thermo 
Fisher Scientific). For RNA samples, complementary DNA 
synthesis was performed using the High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems). Gene ex-
pression profiling was performed on sample duplicates using 
the 96.96 Biomark Dynamic Array (Fluidigm) according to 
the manufacturer’s advanced protocol (Wong et al., 2010). 
Assays were designed based on EvaGreen chemistry (Bi-
otium), and primers for targeting desired pathways were 
designed accordingly for amplicons of 100–150 bp using 
Primer3Plus (Table S2; Untergasser et al., 2007). In brief, 
cDNA was subjected to preamplification (specific target 
amplification [STA]) with a mix of primers specific for the 
target genes. STA was performed by denaturing at 95°C for 
15 s and annealing/amplification at 60°C for 4 min, which 
was repeated for 15 cycles. STA products were then diluted 
fivefold in DNA suspension buffer according to the man-
ufacturer’s instructions (Fluidigm) and supplemented with 
TaqMan Gene Expression Master Mix (Thermo Fisher Sci-
entific) and EvaGreen DNA binding dye (Biotium). Samples 
and primers were loaded into the integrated fluidic circuits 
of the 96.96 Dynamic Array, and analysis was performed 
on a BioMark HD System (Fluidigm). Cycle threshold (Ct) 
values were calculated and visualized using BioMark re-
al-time PCR analysis software (Fluidigm).
As a quality-control measure, we removed genes 
with Ct values of ≥32.0 or differences of ≥2.0 in-be-
tween sample duplicates. If the reference genes (ACTB 
and GAP DH) were not expressed or were removed be-
cause of the aforementioned criteria, the sample was not 
included in further analysis.
Raw values were normalized using the geometric mean 
of the two reference genes (ACTB and GAP DH). The fold 
difference for each sample was calculated using the com-
parative Ct method (Livak and Schmittgen, 2001). Relative 
gene expression quantities after log2 transformation were used 
for unsupervised hierarchical clustering of differentially ex-
pressed genes using standard Pearson’s correlation as similar-
ity measurement and Ward’s method for clustering the data 
(Radpour et al., 2011).
Go enrichment analysis
GO enrichment was assessed using Genomics Suite soft-
ware, version 6.6 (Partek Inc.). The list of significantly 
differently expressed genes was grouped into functional hi-
erarchies, and enrichment scores were calculated using a χ2 
test comparing the proportion of the gene list in a group 
to the proportion of the background in the group. A value 
of three or higher corresponds to differential expression 
of a pathway (P < 0.05).
cell signaling and in silico pathway analysis
Gene networks and canonical pathways representing differ-
entially expressed genes were identified using the Ariadne 
Genomics Pathway Studio software, version 9 (Elsevier). The 
dataset containing gene identifiers and corresponding fold 
changes was uploaded into the Pathway Studio. The func-
tional analysis identified the direct interactions between dif-
ferentially expressed genes and selected pathways to facilitate 
the understanding beyond their regulatory networks.
Microarray data
Expression data were derived from a public repository for 
microarray data (GEO) and are available under accession nos. 
GSE4170 (Radich et al., 2006), GSE12417 (Metzeler et al., 
2008), and GSE1159 (Valk et al., 2004).
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Statistical analysis
Statistical analysis was performed using Prism 5.0 (Graph-
Pad Software) and SAS 9.3 (SAS Institute). Data are repre-
sented as mean ± SEM. Data were analyzed using one-way 
ANO VA and Tukey’s or Dunnett’s multiple comparison test, 
two-way ANO VA, and Bonferroni post-test, unpaired or 
paired Student’s t test (two-tailed), or Mann–Whitney test. 
Receiver operating characteristic curve analysis was used 
to identify the optimal threshold for sCD27 for subsequent 
survival analysis. In brief, 30% of the entire patient cohort 
(n = 41) was randomly selected, and receiver operating 
characteristic curve analysis was performed. To verify the 
reliability of the cutoff, 200 bootstrapped replications were 
performed. Next, all patients were then classified as low or 
high according to the cutoff. Univariate survival analysis was 
performed. Survival time differences were plotted using Ka-
plan-Meier curves and analyzed using the log-rank test. After 
verification of the proportional hazards assumption, multiple 
Cox regression analysis was performed using the continuous 
sCD27 values. Effect size was determined using hazard ratios 
(HRs) and 95% confidence intervals, with a baseline hazard 
of 1.0 and a greater risk of death with HR >1.0. All P values 
were two-sided and considered significant when P < 0.05.
online supplemental material
Fig. S1 shows the FACS gating strategy to identify the CD45dim 
SSClo blast gate in healthy individuals and the gating strategy 
for AML CD45dimSSClolin−CD90−CD34+ stem/progenitor 
cells. Table S1 lists the characteristics of AML patients, healthy 
controls, and patients who underwent BM biopsy for other 
reasons than leukemia. Table S2 lists the primer sequences 
used for qRT-PCR and the 96.96 Biomark Dynamic Array.
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